Cargando…

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended. We conducted a retrospective study to evaluate the impact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lau, David K., Fong, Caroline, Arouri, Faten, Cortez, Lillian, Katifi, Hannah, Gonzalez-Exposito, Reyes, Razzaq, Muhammad Bilal, Li, Su, Macklin-Doherty, Aislinn, Hernandez, Monica Arenas, Hubank, Michael, Fribbens, Charlotte, Watkins, David, Rao, Sheela, Chau, Ian, Cunningham, David, Starling, Naureen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131438/ https://www.ncbi.nlm.nih.gov/pubmed/37101114 http://dx.doi.org/10.1186/s12885-023-10857-8

Ejemplares similares

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
por: Maslarinou, Anthi, et al.
Publicado: (2023)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2018)

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
por: García-Alfonso, P., et al.
Publicado: (2021)

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2019)

Potential Impact of DPYD Variation on Fluoropyrimidine Drug Response in sub-Saharan African Populations
por: da Rocha, Jorge E. B., et al.
Publicado: (2021)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
por: Del Re, Marzia, et al.
Publicado: (2019)

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
por: De Falco, Vincenzo, et al.
Publicado: (2019)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
por: Ragia, Georgia, et al.
Publicado: (2023)

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
por: Iachetta, Francesco, et al.
Publicado: (2019)

Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients
por: Negarandeh, Reza, et al.
Publicado: (2020)

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
por: Deng, Xunwei, et al.
Publicado: (2020)

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach
por: Villalvazo, Priscila, et al.
Publicado: (2021)

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
por: Desilets, Antoine, et al.
Publicado: (2022)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
por: Begré, Ursina B. M., et al.
Publicado: (2022)

Elevated Risk of Fluoropyrimidine-Associated Toxicity in European Patients with DPYD Genetic Polymorphism: A Systematic Review and Meta-Analysis
por: Kim, Woorim, et al.
Publicado: (2022)

Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study
por: Moussa, Osama, et al.
Publicado: (2022)

Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
por: Saif, Muhammad Wasif, et al.
Publicado: (2020)

Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature
por: Bukhari, Nedal, et al.
Publicado: (2021)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey
por: Moorcraft, Sing Yu, et al.
Publicado: (2016)

Accountability in the NHS: the impact on cancer care
por: Macklin-Doherty, Aislinn
Publicado: (2018)

DPYD, TYMS, TYMP, TK1, and TK2 Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy
por: Huang, Ming-Yii, et al.
Publicado: (2013)

Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study
por: Miarons, Marta, et al.
Publicado: (2023)

Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients
por: Tsiachristas, Apostolos, et al.
Publicado: (2022)

Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study
por: Turkes, Fiona, et al.
Publicado: (2022)

Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience
por: Khan, Khurum, et al.
Publicado: (2015)

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature
por: White, Cassandra, et al.
Publicado: (2021)

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
por: Lau, David, et al.
Publicado: (2020)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study
por: Moorcraft, Sing Yu, et al.
Publicado: (2016)

Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer
por: Woolston, Andrew, et al.
Publicado: (2021)

Frequency of the DPYD * 2A allele in the Czech population
por: Koudová, Monika, et al.
Publicado: (2014)

New advances in DPYD genotype and risk of severe toxicity under capecitabine
por: Etienne-Grimaldi, Marie-Christine, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ie5djjee84lq3hbqkd5a43sv44